Eli Lilly’s (NYSE: LLY) latest acquisition has electrified the biotech world—and sent a clear message that gene editing is no ...

We came across a bullish thesis on Verve Therapeutics, Inc. on Stock Region Research’s Substack by Stock Region. In this ...

Shares of Verve Therapeutics skyrocketed 75% Tuesday morning after Eli Lilly announced that it would acquire the gene-editing startup for about $1.3 billion.

Fintel reports that on June 27, 2025, BMO Capital downgraded their outlook for Verve Therapeutics (NasdaqGS:VERV) from Outperform to Market Perform. Analyst Price Forecast Suggests 27.12% Upside As of ...

Lilly is acquiring an exciting new program with the agreement to buy Verve Therapeutics. Shares in Verve Therapeutics (NASDAQ: VERV) soared 80.5% this week on the news of an agreement for Eli Lilly ...

Is it too late to buy Verve Therapeutics stock? Usually, when an acquisition of a clinical-stage drugmaker is announced, investors don't have much incentive to buy the small biotech stock before ...

Verve Therapeutics is at the forefront of gene-editing technology applied to cardiovascular diseases. The company’s lead asset, VERVE-102, targets PCSK9 to reduce LDL cholesterol levels in ...

Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage company developing a new class of genetic medicines for cardiovascular disease with the potential to transform treatment from chronic ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Verve Therapeutics (NASDAQ:VERV – Get Free Report) was downgraded by stock analysts at HC Wainwright from a “buy” rating to a “neutral” rating in a research report issued on Wednesday ...

Eli Lilly acquires Verve Therapeutics, Inc. for $1B to advance gene-editing therapies like VERVE-102, targeting ASCVD. Click for more on LLY and VERV.